Quick Answer
TherapeuticsMD, Inc. reported Operating Income Loss of -$4.39 million for the year ending 2025.
- TherapeuticsMD, Inc. showed an increase of +28.2% in Operating Income Loss from 2024 to 2025.
- This data is from TherapeuticsMD, Inc.'s annual report (Form 10-K), filed with the SEC on March 30, 2026.
- XBRL data for this metric is available from 2011 to 2025 (15 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2011: -$771.4 thousand | Q2 2011: -$1.05 million | Q3 2011: -$1.44 million | Q1 2012: -$2.87 million | Q2 2012: -$3.97 million | Q3 2012: -$3.91 million | Q1 2013: -$4.94 million | Q2 2013: -$5.62 million | Q3 2013: -$7.24 million | Q1 2014: -$8.95 million | Q2 2014: -$10.93 million | Q3 2014: -$17.85 million | Q1 2015: -$20.92 million | Q2 2015: -$27.26 million | Q3 2015: -$19.50 million | Q1 2016: -$20.97 million | Q2 2016: -$21.21 million | Q3 2016: -$25.13 million | Q1 2017: -$21.29 million | Q2 2017: -$19.83 million | Q3 2017: -$14.83 million | Q1 2018: -$24.72 million | Q2 2018: -$33.02 million | Q3 2018: -$34.36 million | Q1 2019: -$38.11 million | Q2 2019: -$41.64 million | Q3 2019: -$27.07 million | Q1 2020: -$50.92 million | Q2 2020: -$45.04 million | Q3 2020: -$24.97 million | Q4 2020: -$34.61 million | Q1 2021: -$29.28 million | Q2 2021: -$35.18 million | Q3 2021: -$39.92 million | Q4 2021: -$35.39 million | Q1 2022: -$17.88 million | Q2 2022: -$14.86 million | Q3 2022: -$14.52 million | Q1 2023: -$2.67 million | Q2 2023: -$2.47 million | Q3 2023: -$1.77 million | Q1 2024: -$1.14 million | Q2 2024: -$2.79 million | Q3 2024: -$1.13 million | Q1 2025: -$871.0 thousand | Q2 2025: -$695.0 thousand | Q3 2025: -$862.0 thousand.
- Over the full 15 years of available data (2011 to 2025), TherapeuticsMD, Inc.'s Operating Income Loss has grown by 19.1%.
- Historical annual values: Fiscal year 2025: -$4.39 million | Fiscal year 2024: -$6.11 million | Fiscal year 2023: -$8.52 million | Fiscal year 2022: $1.19 million | Fiscal year 2021: -$79.58 million | Fiscal year 2020: -$155.54 million | Fiscal year 2019: -$151.21 million | Fiscal year 2018: -$130.22 million | Fiscal year 2017: -$77.63 million | Fiscal year 2016: -$90.25 million | Fiscal year 2015: -$85.19 million | Fiscal year 2014: -$54.04 million | Fiscal year 2013: -$25.81 million | Fiscal year 2012: -$16.15 million | Fiscal year 2011: -$5.43 million.
- Data sourced from SEC EDGAR public filings as of August 7, 2026.
Last verified: